title: Erythropoietin in human fetuses with immune hemolytic anemia and hydrops fetalis.
abstract: OBJECTIVE
  To determine whether plasma erythropoietin is increased in fetuses with anemia due to Rh isoimmunization.
  
  
  METHODS
  Hemoglobin and erythropoietin were measured in samples obtained by funipuncture from 15 fetuses with Rh isoimmunization (gestational age 26.2 +/- 5.0 weeks, mean +/- standard deviation) and from 13 control fetuses (23.1 +/- 6.7 weeks). Hemoglobin and erythropoietin also were determined in umbilical cord blood collected at birth from 20 term fetuses delivered by elective cesarean.
  
  
  RESULTS
  Fetuses with Rh isoimmunization had lower hemoglobin and higher plasma erythropoietin measurements than mid-gestation controls (6.1 +/- 3.9 versus 10.7 +/- 1.5 g/dL and 105.5 +/- 168.1 versus 12.5 +/- 3.1 mU/mL, P < .05, respectively). Hemoglobin and plasma erythropoietin increased with gestational age in control fetuses. There was an inverse association between hemoglobin and plasma erythropoietin in control and Rh-isoimmunized fetuses (r = -0.56, P < .005). Using multiple linear regression, hemoglobin and gestational age were associated independently with plasma erythropoietin (overall F2,25 = 12.3, multiple r2 = 0.49, P < .001). Despite marked decreases in hemoglobin, fetuses below 24 weeks' gestation had minimal increases in plasma erythropoietin compared to fetuses above that gestational age. Mildly anemic Rh-isoimmunized fetuses (hemoglobin 11.6 +/- 2.0 g/dL) delivered vaginally had significantly higher erythropoietin levels in umbilical cord plasma than Rh-isoimmunized fetuses with comparable hemoglobin (10.9 +/- 3.5 g/dL) delivered by elective cesarean without labor (1246 +/- 856 versus 106 +/- 66 mU/mL, respectively, P < .05).
  
  
  CONCLUSIONS
  Fetuses with anemia at mid to late gestation respond with increases in plasma erythropoietin, but these changes are substantially attenuated before 24 weeks' gestation.
authors.affiliation: Department of Pediatrics, Yale University, New Haven, Connecticut.
authors.forename: F R
authors.initials: FR
authors.lastname: Moya
authors.forename: P A
authors.initials: PA
authors.lastname: Grannum
authors.forename: J A
authors.initials: JA
authors.lastname: Widness
authors.forename: G K
authors.initials: GK
authors.lastname: Clemons
authors.forename: J A
authors.initials: JA
authors.lastname: Copel
authors.forename: J C
authors.initials: JC
authors.lastname: Hobbins
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood* / Q000150:complications / Q000628:therapy; D001805:Blood Transfusion, Intrauterine; D004921:Erythropoietin / Q000097:blood*; D005312:Fetal Blood; D005315:Fetal Diseases / Q000097:blood* / Q000628:therapy; D005865:Gestational Age; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D015160:Hydrops Fetalis / Q000097:blood* / Q000150:complications / Q000628:therapy; D012044:Regression Analysis; D012203:Rh Isoimmunization / Q000097:blood* / Q000150:complications / Q000628:therapy
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin